ACUTE MYELOID LEUKEMIAS
Clinical trials for ACUTE MYELOID LEUKEMIAS explained in plain language.
Never miss a new study
Get alerted when new ACUTE MYELOID LEUKEMIAS trials appear
Sign up with your email to follow new studies for ACUTE MYELOID LEUKEMIAS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for hard-to-treat leukemias: targeted combo enters human testing
Disease control Recruiting nowThis early-phase study tests a new drug called SNDX-5613 combined with strong chemotherapy in people newly diagnosed with acute myeloid leukemia (AML) that has specific gene changes (KMT2A, NPM1, or NUP98). The main goals are to check safety and find the best dose. About 76 adult…
Matched conditions: ACUTE MYELOID LEUKEMIAS
Phase: PHASE1 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New hope for Hard-to-Treat leukemias: first human trial begins
Disease control Recruiting nowThis early-stage study tests a new drug called STX-0712 in people with advanced types of leukemia (CMML or AML) that have not responded to other treatments. The main goals are to find a safe dose and check for side effects. About 105 adults will take part in this first-in-human t…
Matched conditions: ACUTE MYELOID LEUKEMIAS
Phase: PHASE1 • Sponsor: Solu Therapeutics, Inc • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New combo therapy shows promise in leukemia trial
Disease control Recruiting nowThis study tests whether adding the drug revumenib to standard chemotherapy helps people with a certain genetic type of acute myeloid leukemia (AML) live longer without the cancer coming back. About 468 adults with newly diagnosed AML and an NPM1 mutation will receive either revu…
Matched conditions: ACUTE MYELOID LEUKEMIAS
Phase: PHASE3 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated May 06, 2026 16:14 UTC